JMP Securities Maintains Market Outperform on Tremor Intl, Lowers Price Target to $20
JMP Securities analyst Andrew Boone maintains Tremor Intl (NASDAQ:TRMR) with a Market Outperform and lowers the price target from $22 to $20.
Where Tremor Intl Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on Tremor Intl (NASDAQ:TRMR) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday’s Mid-Day Session
Gainers
Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target.
Tremor Sees Q4 Contribution ex-TAC of ~$103M; Adjusted EBITDA ~$37M
Tremor remains well-positioned to benefit from anticipated industry secular growth trends and Company-specific catalysts including the FIFA World Cup, the completed acquisition of Amobee, and its investment in VIDAA, and
Tremor Intl Q3 Adj. EPS $0.11 Misses $0.24 Estimate, Sales $70.85M Miss $75.26M Estimate
Tremor Intl (NASDAQ:TRMR) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.24 by 54.17 percent. This is a 47.62 percent decrease over earnings of $0.21 per share from the
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
